| Revenue Growth | Total revenue up 32%; Voxogo up 12% to $245M; Gallifold $152M. |
|---|---|
| Mgmt Confidence | Confident in underlying demand despite $70M order deferral and geopolitical headwinds. |
| Demand Visibility | Strong patient demand; Voxogo children treated increased 17% worldwide. |
| Order Book | $70M in expected orders deferred from Q4 to Q1 2027. |
| Margin Trends | Non-GAAP SG&A increased 12%; Amicus cost synergies ahead of schedule. |
| Op. Leverage | Non-GAAP SG&A growth of 12% significantly lagged 32% revenue growth. |
| Vol vs Price | Growth volume-led; Pombiliti/Opfolda patients increased 69% year-over-year. |
| Segment Growth | Metabolic conditions grew 44%; Voxogo 75% revenue from outside US. |
| New Clients | Added 3 international markets for Voxogo; Pombiliti market leader in 4 European markets. |
| Capex & Debt | Acquired Alesta for $320M IPR&D; BMN 450 license for $83M upfront. |
| Regulatory | Voxogo hypochondroplasia PDUFA May 30, 2027; BMN 820 full approval PDUFA Feb 2027. |
| Commentary | Strategic shift toward clinical-stage acquisitions to diversify rare disease portfolio. |
| New Launches | Preparing for 2027 hypochondroplasia launch; BMN 450 entering Phase 1/2. |
Growth
Revenue grew 32% year-over-year; metabolic conditions business up 44% driven by Amicus integration.
Outlook
Full-year 2026 revenue guidance updated to $3.8B-$3.9B; Voxogo hypochondroplasia PDUFA set for May 2027.
Risks
Management lowered revenue guidance by $100M due to timing uncertainty and Middle East liquidity issues.
The company's earnings call, NASDAQ: BMRN, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Biomarin Pharmaceutical Inc: key numbers
- Share price
- $57.99Close, Nov 16
- Market cap
- $11.2B
- Shares outstanding
- 193.69MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biomarin Pharmaceutical Inc
All →Biomarin Pharmaceutical Q3 2026 Results: Net Loss of $123M, Loss Widens
BioMarin reported total revenues of $1.02 billion for the third quarter of 2026, a significant increase from $776.1 million in the prior year, though it recorded a net loss of $122.8 million due to higher operating expenses and intangible asset amortization. The company's balance sheet expanded significantly following a $5.07 billion business combination, funded in part by $3.65 billion in new borrowings.
- Key figure
- Net loss $123M
Biomarin Pharmaceutical Financial Results
BioMarin reported third-quarter 2026 financial results, achieving a milestone of over $1 billion in quarterly revenue, a 32% year-over-year increase. Growth was driven by the acquisition of Amicus Therapeutics and strong demand for metabolic and skeletal condition treatments. The company also announced an FDA PDUFA date of May 30, 2027, for the potential expansion of VOXZOGO into hypochondroplasia.
- Term
- Q3 2026
“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world. For the first time, quarterly revenue exceeded $1 billion, a milestone for BioMarin.”
Alexander Hardy, President and Chief Executive Officer
“As we approach 2027, we are well positioned for our next chapter of growth, including the potential launch of VOXZOGO in hypochondroplasia and the continued execution of our financial and innovation strategy.”
Alexander Hardy, President and Chief Executive Officer
Biomarin Pharmaceutical Business Update
BioMarin disclosed the estimated financial impact of its August 31, 2026, acquisition of Alesta Therapeutics, including a $283 million pre-tax charge for acquired in-process research and development (IPR&D). The acquisition is expected to have a $1.50 unfavorable impact on Q3 2026 EPS and a $1.55 impact on full-year 2026 EPS, with updated full-year guidance to be provided during the Q3 earnings call.
- Counterparty
- Alesta Therapeutics B.V.
Biomarin Pharmaceutical Licensing Deal with Ascendis Pharma A/S
BioMarin entered into a definitive Settlement and License Agreement with Ascendis Pharma, granting Ascendis a non-exclusive worldwide license to certain patents for the commercialization of TransCon CNP (navepegritide). In exchange, BioMarin will receive royalties of 20% on net sales in the U.S. and 18% in the EU, Brazil, and South Korea through May 2030, while both parties agreed to dismiss all pending patent litigation.
- Counterparty
- Ascendis Pharma A/S
- Term
- through May 2030
Biomarin Pharmaceutical Other 8-K Filing
BioMarin Pharmaceutical Inc. announced its decision to discontinue the clinical development of VOXZOGO for children with Noonan syndrome. The company cited study feasibility and the current treatment landscape as reasons for the move, noting the decision was not related to safety or efficacy.
Biomarin Pharmaceutical Executive Compensation
BioMarin Pharmaceutical Inc. increased its board size from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., as an independent director. Dr. Plenge will receive standard non-employee director fees and was granted restricted stock units (RSUs) valued at $400,000, which vest just prior to the company's next annual meeting.
- Counterparty
- Robert Plenge